Oxaceprol: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
No edit summary |
||
Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name | | verifiedrevid = 447917039 | ||
| image | | IUPAC_name = (4''R'')-1-acetyl-4-hydroxy-<small>L</small>-proline | ||
| width | | image = Oxaceprol.svg | ||
| width = 200px | |||
| | |||
| | <!--Clinical data--> | ||
| tradename = | |||
| Drugs.com = {{drugs.com|international|oxaceprol}} | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = <!-- A / B / C / D / X --> | |||
| pregnancy_category = | |||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | |||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | |||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | |||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | |||
| legal_status = | |||
| pregnancy_AU | | routes_of_administration = | ||
| pregnancy_US | |||
| pregnancy_category= | <!--Pharmacokinetic data--> | ||
| legal_AU | | bioavailability = | ||
| legal_CA | | protein_bound = | ||
| legal_UK | | metabolism = | ||
| legal_US | | elimination_half-life = | ||
| legal_status = | | excretion = | ||
| | |||
<!--Identifiers--> | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 33996-33-7 | |||
| ATC_prefix = D11 | |||
| ATC_suffix = AX09 | |||
| ATC_supplemental = {{ATC|M01|AX24}} | |||
| PubChem = 65784 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = Q0XV76B96L | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D07215 | |||
| ChemSpiderID = 59203 | |||
| ChEMBL = 1407356 | |||
<!--Chemical data--> | |||
| C=7 | H=11 | N=1 | O=4 | |||
| molecular_weight = 172.159 g/mol | |||
| smiles = CC(=O)N1C[C@@H](C[C@H]1C(=O)O)O | |||
| InChI = 1/C7H11NO4/c1-4(9)8-3-5(10)2-6(8)7(11)12/h5-6,10H,2-3H2,1H3,(H,11,12)/t5-,6+/m1/s1 | |||
| InChIKey = BAPRUDZDYCKSOQ-RITPCOANBI | |||
| StdInChI = 1S/C7H11NO4/c1-4(9)8-3-5(10)2-6(8)7(11)12/h5-6,10H,2-3H2,1H3,(H,11,12)/t5-,6+/m1/s1 | |||
| StdInChIKey = BAPRUDZDYCKSOQ-RITPCOANSA-N | |||
| synonyms = <small>(2''S'',4''R'')-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid</small> | |||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | ==Overview== | ||
'''Oxaceprol''' is an anti-inflammatory drug used in the treatment of [[osteoarthritis]].<ref name="pmid10791619">{{cite journal |author=Herrmann G | '''Oxaceprol''' is an anti-inflammatory drug used in the treatment of [[osteoarthritis]].<ref name="pmid10791619">{{cite journal |author=Herrmann G |title=Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac |journal=Clin. Rheumatol. |volume=19 |issue=2 |pages=99–104 |year=2000 |pmid=10791619 |doi=10.1007/s100670050025 |author-separator=, |author2=Steeger D |author3=Klasser M |display-authors=3 |last4=Wirbitzky |first4=J. |last5=füRst |first5=M. |last6=Venbrocks |first6=R. |last7=Rohde |first7=H. |last8=Jungmichel |first8=D. |last9=Hildebrandt |first9=H. D.}}</ref> It is derived from [[L-proline]], a DNA-encoded [[amino acid]]. The active effect of Oxaceprol is to inhibit the adhesion and migration of [[white blood cell]]s.<ref name="Clayton2007"/> | ||
==References== | ==References== | ||
< | {{reflist|refs= | ||
<ref name="Clayton2007">{{Citation | |||
| first1 = James J. | |||
| last1 = Clayton | |||
| title = Nutraceuticals in the Management of Osteoarthritis | |||
| journal = Orthopedics | |||
|date=August 2007 | |||
| volume = 30 | |||
| issue = 8 | |||
| url = http://www.healio.com/orthopedics/journals/ORTHO/%7BD4DA9AAE-37CE-4E4A-9C5E-B518F4CFC952%7D/Nutraceuticals-in-the-Management-of-Osteoarthritis | |||
| accessdate= 2013-06-08 | |||
| postscript= . | |||
}}</ref> | |||
}} | |||
==References== | |||
{{reflist|2}} | |||
{{Other dermatological preparations}} | {{Other dermatological preparations}} | ||
{{Anti-inflammatory and antirheumatic products}} | {{Anti-inflammatory and antirheumatic products}} | ||
[[Category:Pyrrolidines]] | [[Category:Pyrrolidines]] | ||
[[Category:Acetamides]] | |||
[[Category:Alcohols]] | |||
[[Category:Amino acid derivatives]] | |||
[[Category:Drug]] |
Revision as of 17:50, 8 April 2015
File:Oxaceprol.svg | |
Clinical data | |
---|---|
Synonyms | (2S,4R)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C7H11NO4 |
Molar mass | 172.159 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Oxaceprol |
Articles |
---|
Most recent articles on Oxaceprol |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Oxaceprol at Clinical Trials.gov Clinical Trials on Oxaceprol at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Oxaceprol
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Oxaceprol Discussion groups on Oxaceprol Directions to Hospitals Treating Oxaceprol Risk calculators and risk factors for Oxaceprol
|
Healthcare Provider Resources |
Causes & Risk Factors for Oxaceprol |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oxaceprol is an anti-inflammatory drug used in the treatment of osteoarthritis.[1] It is derived from L-proline, a DNA-encoded amino acid. The active effect of Oxaceprol is to inhibit the adhesion and migration of white blood cells.[2]
References
- ↑ Herrmann G; Steeger D; Klasser M; et al. (2000). "Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac". Clin. Rheumatol. 19 (2): 99–104. doi:10.1007/s100670050025. PMID 10791619. Unknown parameter
|author-separator=
ignored (help) - ↑ Clayton, James J. (August 2007), "Nutraceuticals in the Management of Osteoarthritis", Orthopedics, 30 (8), retrieved 2013-06-08.
References
- Pages with script errors
- Pages with citations using unsupported parameters
- Pages with broken file links
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Pyrrolidines
- Acetamides
- Alcohols
- Amino acid derivatives
- Drug